Anthos Logo Transparent.png
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
06 juin 2024 08h15 HE | Anthos Therapeutics
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
Anthos Logo Transparent.png
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
22 avr. 2024 11h09 HE | Anthos Therapeutics
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...
Anthos Logo Transparent.png
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
08 juin 2023 11h10 HE | Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
Anthos Logo Transparent.png
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
08 sept. 2022 08h00 HE | Anthos Therapeutics
This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...
Anthos Logo Transparent.png
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
25 août 2022 08h00 HE | Anthos Therapeutics
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab against the current standard of care for VTE in cancer associated...